Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.
2.

Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.

Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860.

PMID:
23234816
3.

Cassia cinnamon does not change the insulin sensitivity or the liver enzymes in subjects with impaired glucose tolerance.

Wickenberg J, Lindstedt S, Nilsson J, Hlebowicz J.

Nutr J. 2014 Sep 24;13:96. doi: 10.1186/1475-2891-13-96.

4.

The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.

Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, Konturek SJ.

J Physiol Pharmacol. 2010 Dec;61(6):705-10.

5.

Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.

Farhangi MA, Alipour B, Jafarvand E, Khoshbaten M.

Arch Med Res. 2014 Oct;45(7):589-95. doi: 10.1016/j.arcmed.2014.11.001.

PMID:
25450583
6.

[Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].

Zheng LY, Pan JQ, Lv JH.

Zhongguo Zhong Yao Za Zhi. 2008 Oct;33(20):2385-90. Chinese.

PMID:
19157135
7.

Acetyl-L-carnitine and lipoic acid improve mitochondrial abnormalities and serum levels of liver enzymes in a mouse model of nonalcoholic fatty liver disease.

Kathirvel E, Morgan K, French SW, Morgan TR.

Nutr Res. 2013 Nov;33(11):932-41. doi: 10.1016/j.nutres.2013.08.001.

PMID:
24176233
8.

The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study.

Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, Konturek SJ.

J Physiol Pharmacol. 2012 Feb;63(1):35-40.

9.

Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial.

Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, Yiu KK, Yu J, Chan FK, Chan HL.

J Gastroenterol Hepatol. 2013 Jan;28(1):57-62. doi: 10.1111/j.1440-1746.2012.07286.x.

PMID:
23034128
10.
11.

[Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].

Zhang DM, Zhang GY, Wang T, Zhong HJ, Chen WK.

Zhonghua Yi Xue Za Zhi. 2006 May 16;86(18):1279-83. Chinese.

PMID:
16796890
12.

Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.

Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F.

Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1182-7. doi: 10.1016/j.numecd.2013.01.006.

PMID:
23419734
13.

The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease.

Karandish M, Tamimi M, Shayesteh AA, Haghighizadeh MH, Jalali MT.

J Res Med Sci. 2013 Jul;18(7):573-9.

14.

Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats.

Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY.

J Zhejiang Univ Sci B. 2006 Aug;7(8):627-33.

15.

Irisin in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS.

Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013.

PMID:
24140091
16.

Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis.

Wang L, Meng X, Zhang F.

J Med Food. 2012 May;15(5):495-503. doi: 10.1089/jmf.2011.1717.

17.

Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease.

Esteghamati A, Noshad S, Khalilzadeh O, Khalili M, Zandieh A, Nakhjavani M.

Metab Syndr Relat Disord. 2011 Apr;9(2):111-7. doi: 10.1089/met.2010.0066.

PMID:
21091060
18.

[Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease].

Liu M, Yan HM, Gao X, Gao J.

Zhonghua Yi Xue Za Zhi. 2007 Jan 23;87(4):253-5. Chinese.

PMID:
17425870
19.

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.

Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW.

World J Gastroenterol. 2008 Nov 7;14(41):6395-400.

20.

The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.

Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, Suman A, Weber M, Cusi K.

Hepatology. 2015 Jan;61(1):153-60. doi: 10.1002/hep.27395.

PMID:
25145475
Items per page

Supplemental Content

Support Center